NO20031185L - Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel - Google Patents

Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel

Info

Publication number
NO20031185L
NO20031185L NO20031185A NO20031185A NO20031185L NO 20031185 L NO20031185 L NO 20031185L NO 20031185 A NO20031185 A NO 20031185A NO 20031185 A NO20031185 A NO 20031185A NO 20031185 L NO20031185 L NO 20031185L
Authority
NO
Norway
Prior art keywords
cytokine
selectokine
antibody
target
fusion protein
Prior art date
Application number
NO20031185A
Other languages
English (en)
Other versions
NO20031185D0 (no
Inventor
Thomas Wuerst
Dieter Moosmayer
Matthias Grell
Peter Scheurich
Original Assignee
Pfizenmaier Klaus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizenmaier Klaus filed Critical Pfizenmaier Klaus
Publication of NO20031185D0 publication Critical patent/NO20031185D0/no
Publication of NO20031185L publication Critical patent/NO20031185L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20031185A 2000-09-15 2003-03-14 Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel NO20031185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (2)

Publication Number Publication Date
NO20031185D0 NO20031185D0 (no) 2003-03-14
NO20031185L true NO20031185L (no) 2003-05-05

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031185A NO20031185L (no) 2000-09-15 2003-03-14 Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel

Country Status (22)

Country Link
US (1) US20040053829A1 (no)
EP (1) EP1317556A1 (no)
JP (1) JP2004508828A (no)
KR (1) KR20030048041A (no)
CN (1) CN1214115C (no)
AU (1) AU2001293819A1 (no)
BG (1) BG107613A (no)
BR (1) BR0113928A (no)
CA (1) CA2422759A1 (no)
DE (1) DE10045592A1 (no)
EE (1) EE200300100A (no)
HR (1) HRP20030192A2 (no)
HU (1) HUP0301693A3 (no)
IL (1) IL154185A0 (no)
MX (1) MXPA03002229A (no)
NO (1) NO20031185L (no)
PL (1) PL360540A1 (no)
RU (1) RU2003106429A (no)
SK (1) SK2812003A3 (no)
WO (1) WO2002022833A1 (no)
YU (1) YU18903A (no)
ZA (1) ZA200302008B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043773A2 (en) * 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CA2515100A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring t cell response
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
JP7515412B2 (ja) * 2018-03-09 2024-07-12 アスクジーン・ファーマ・インコーポレイテッド 新規のサイトカインプロドラッグ
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
JP2021530243A (ja) * 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規il−21プロドラッグおよびそれを使用する方法
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
WO2020252264A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
NO20031185D0 (no) 2003-03-14
BR0113928A (pt) 2003-07-22
HRP20030192A2 (en) 2005-10-31
YU18903A (sh) 2006-05-25
WO2002022833A1 (de) 2002-03-21
SK2812003A3 (en) 2003-11-04
JP2004508828A (ja) 2004-03-25
CN1214115C (zh) 2005-08-10
CA2422759A1 (en) 2003-03-17
AU2001293819A1 (en) 2002-03-26
IL154185A0 (en) 2003-07-31
RU2003106429A (ru) 2004-08-27
EE200300100A (et) 2005-02-15
HUP0301693A3 (en) 2005-11-28
US20040053829A1 (en) 2004-03-18
DE10045592A1 (de) 2002-03-28
EP1317556A1 (de) 2003-06-11
ZA200302008B (en) 2004-06-25
CN1458977A (zh) 2003-11-26
BG107613A (bg) 2003-12-31
KR20030048041A (ko) 2003-06-18
HUP0301693A2 (hu) 2003-08-28
PL360540A1 (en) 2004-09-06
MXPA03002229A (es) 2005-06-20

Similar Documents

Publication Publication Date Title
NO20031185L (no) Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1286989T3 (da) Prodrug fra en ICE
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
DE60136416D1 (de) Kraftverstärkender Mechanismus für Hefter
DE60115817D1 (de) Nickel-Basis-Hartlotlegierung
DE60129982D1 (de) Schweisshemmende zusammensetzungen
DE60116311D1 (de) Schweisshemmende zusammensetzungen
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DE60017273D1 (de) Laserschweisssystem
DK1571140T3 (da) Substituerede C-cyjklohexylmethylamin-derivater
DK1442026T3 (da) Triazolderivater som cyclooxygenase (COX)-inhibitorer
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
ATE272045T1 (de) Substituierte 1-aminobutan-3-ol-derivate
IT250181Y1 (it) Custodia perfezionata per rivoltella
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DE50107634D1 (de) Faltschachtel
DE60130423D1 (de) Festkörperlaser
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
ITNO20000008A0 (it) Progetto anubi
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater
FI20002674A0 (fi) Rimarakennemuotti
NO20010900D0 (no) Oksamider som IMPDH-inhibitorer